Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Editas Medicine, Inc. (EDIT : NSDQ)

• Company Description    Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature. Number of Employees: 246

• Price / Volume Information    Yesterday's Closing Price: $2.57 Daily Weekly Monthly 20 Day Moving Average: 2,882,953 shares Shares Outstanding: 83.71 (millions) Market Capitalization: $215.14 (millions) Beta: 2.15 52 Week High: $6.05 52 Week Low: $0.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 34.56% 28.58% 12 Week 97.69% 68.85% Year To Date 102.36% 89.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11 Hurley Street - Cambridge,MA 02141 USA ph: 617-401-9000 fax: - ir@editasmed.com http://www.editasmedicine.com

• General Corporate Information    Officers Gilmore O Neill - President and Chief Executive Officer Jessica Hopfield - Chairman of the Board Erick Lucera - Chief Financial Officer Bernadette Connaughton - Director Andrew Hirsch - Director Peer Information Editas Medicine, Inc. (CORR.) Editas Medicine, Inc. (RSPI) Editas Medicine, Inc. (CGXP) Editas Medicine, Inc. (BGEN) Editas Medicine, Inc. (GTBP) Editas Medicine, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28106W103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 83.71 Most Recent Split Date: (:1) Beta: 2.15 Market Capitalization: $215.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 40.39% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.45 Price/Cash Flow: - Price / Sales: 6.00 EPS Growth vs. Year Ago Period: 43.42% vs. Previous Quarter: 21.82% Sales Growth vs. Year Ago Period: 310.40% vs. Previous Quarter: -84.78% ROE 06/30/25 - - 03/31/25 - -139.24 12/31/24 - -113.40 ROA 06/30/25 - - 03/31/25 - -63.87 12/31/24 - -63.47 Current Ratio 06/30/25 - - 03/31/25 - 3.08 12/31/24 - 3.75 Quick Ratio 06/30/25 - - 03/31/25 - 3.08 12/31/24 - 3.75 Operating Margin 06/30/25 - - 03/31/25 - -587.06 12/31/24 - -733.74 Net Margin 06/30/25 - - 03/31/25 - -701.06 12/31/24 - -733.74 Pre-Tax Margin 06/30/25 - - 03/31/25 - -701.06 12/31/24 - -733.72 Book Value 06/30/25 - - 03/31/25 - 0.75 12/31/24 - 1.63 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©